Company Overview
| Stock Name | Heartcare-B |
|---|---|
| Stock Code | 06609 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事研發、制造及銷售神經介入及心臟醫療器械。 |
| Listing Date | 2021-08-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市張江高科技產業東區瑞慶路590號9幢南2層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.heartcare.com.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 171.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 45.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 564,471,000 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 129.0 |
|---|---|
| First Day Open | HK$ 141.2 |
| First Day Change | -24.56% |
| First Day Volume | 2053800.0 |
| First Day Turnover | 281742000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品； 2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品； 3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金； 4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 2 | Aspex Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 3 | Boyu Capital Opportunities Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 4 | Goldstream Healthcare Focus Fund SP | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 6 | LYFE CAPITAL FUND III (DRAGON), L.P. | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 7 | Octagon Investments Master Fund LP | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 8 | Sage Partners Master Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 9 | Superstring Capital Master Fund LP | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 10 | The Valliance Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
Directors & Management
| Chairman | 王國輝 |
|---|---|
| Company Secretary | 張涵,歐陽偉 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王國輝(29.2%);LYFE Capital Management Limited(13.64%) |
|---|
